- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Lupin Limited — Updates, 23-02-2026: Press Release
23-02-2026 | 03:27 pm
23-02-2026 | 03:27 pm
Lupin secured European Commission approval for its biosimilar Ranibizumab (RanluspecTM). This paves the way for commercialization by Sandoz across most of the EU, expanding market access and potential revenue streams for this key biologic therapy.
No comments yet. Be the first to comment!